NBIX — NEUROCRINE BIOSCIENCES INC

—
Nasdaq · Health Care · Biotechnology · CIK 914475 ·
Last close
$165.92
Market Cap
$16.79B
52W High
$186.12
52W Low
$122.14
ADV30
1,382,547
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 959,000,000 935,800,000 153,000,000 144,400,000 5,359,100,000 332,400,000 1,665,500,000
Mar 2026 814,500,000 800,700,000 186,000,000 197,900,000 4,906,200,000 266,500,000 1,498,800,000
Dec 2025 805,500,000 787,900,000 227,900,000 153,700,000 4,631,500,000 713,000,000 1,378,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,065,800,000
Investing CF
$-705,600,000
Financing CF
$-60,400,000
CapEx
$-41,700,000
Dividends Paid
—
Buybacks
$-158,100,000
EPS Diluted TTM
$6.74
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$838,400,000
Inventory
$66,100,000
Receivables
$957,300,000
ST Investments
$96,400,000
EBIT TTM
$863,000,000
Pretax Income TTM
$932,100,000
Interest Exp TTM
$3,200,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,701,700,096
EBITDA
$1,069,100,032
Free Cash Flow
$1,018,237,504
Enterprise Value
$16,377,525,248
Total Cash
$737,900,032
Total Debt
$451,800,000
Shares Out
101,218,643
Trailing EPS
$6.74
Book Value
$38.29
ROE
20.4%
ROA
12.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,860,500,000 636,500,000 478,600,000 4,631,500,000 1,378,400,000 3,253,100,000 782,700,000
Dec 2024 2,355,300,000 583,000,000 341,300,000 3,718,700,000 1,129,000,000 2,589,700,000 595,400,000
Dec 2023 1,887,100,000 394,800,000 249,700,000 3,251,400,000 1,019,400,000 2,232,000,000 389,900,000
Dec 2022 1,488,700,000 249,000,000 154,500,000 2,368,700,000 660,900,000 1,707,800,000 339,400,000

TTM Snapshot

Revenues TTM
$3,373,900,000
NetIncome TTM
$705,500,000
OpCashFlow TTM
—
Assets (Latest)
$5,359,100,000
Forward EPS
$12.09

Max Pain — expiry 2027-12-17

max pain strike: $145.00 · spot: $162.86 · call oi: 6,113 · put oi: 82
Expected Move to 2027-12-17: ±$61.54 (37.79%) — implied range $101.32 – $224.40 · ATM straddle on $165.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EXEL EXELIXIS, INC. $16.71B $68.50 —
BNTX BioNTech SE $21.32B $84.86 —
TECH BIO-TECHNE Corp $11.41B $72.63 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —

News headlines (Yahoo Finance, 1h cache)

Neurocrine Biosciences (NBIX) Stock Still Looks Undervalued As Its 89% Run Draws Focus
2026-11-18 10:13 · Yahoo
Should You Buy Neurocrine Biosciences Stock For Its Cash?
2026-11-16 11:42 · Yahoo
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
2026-11-10 21:01 · Yahoo
NBIX or GRDN: Which Is the Better Value Stock Right Now?
2026-11-10 19:38 · Yahoo
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
2026-11-09 16:45 · Yahoo
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
2026-11-09 16:00 · Yahoo
NBIX vs. GRDN: Which Stock Is the Better Value Option?
2026-11-09 15:40 · Yahoo
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
2026-11-09 13:55 · Yahoo
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
2026-11-05 13:30 · Yahoo
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
2026-11-03 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.